Two years after spelling out its off-the-shelf Car-T ambitions Celyad has some early human data to go on. A presentation at the upcoming European Hematology Association meeting is set to detail the first multiple myeloma patients given CYAD-211, an allogeneic anti-BCMA construct that uses shRNA to silence endogenous T-cell receptors without gene editing. An abstract released this week shows one partial remission among two fifth-line subjects, with – importantly – no graft-versus-host disease in either. At the June 11 EHA session analysts hope to see data on further patients, perhaps at a higher cell dose. Another cell therapy player, Autolus, spiked this week on continued promise from its Car-T asset, Auto1, with its EHA abstract showing 100% complete remission in indolent lymphoma, and a remarkably low rate of neurotoxicity and cytokine release. Still, this is one of a multitude of projects targeting CD19. Investors are also keenly awaiting data at EHA from Forma’s FT-4202, a mechanistic rival to Agios’s mitapivat that impressed at Ash, though for now the biggest beneficiary of EHA appears to have been Curis.
|Selected early clinical data being presented at the European Hematology Association conference|
|CYAD-211||Celyad||4L multiple myeloma (Immunicity-1/ NCT04613557)||1/2 PR rate; no GvHD||EP739|
|Auto1||Autolus||r/r indolent B-cell lymphomas (NCT02935257)||9/9 CR rate; no CRS above gr2; no ICANS||EP788|
|FT-4202||Forma||Sickle cell disease (NCT03815695)||Data from 600mg & 12wk open-label 400mg doses to be presented||EP1202|
|BGB-11417||Beigene||Non-Hodgkin's lymphoma (NCT04277637)||Novel Bcl2 inhibitor; safety data only in abstract||EP525|
|Source: EHA abstracts.|
The virtual EHA conference will take place June 9-12.